ESABMEDIUM SIGNALOPERATIONAL10-K

ESAB completed four acquisitions in 2025 (up from three in 2024) while experiencing declining profitability and cash generation despite significant asset growth.

The company is actively pursuing growth through acquisitions, evidenced by the increased M&A activity and substantial asset base expansion. However, the deterioration in operating cash flow and net income suggests integration challenges or margin pressure that investors should monitor closely.

Comparing 2026-02-20 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

ESAB's financial profile shows a company in growth mode with mixed results - total assets expanded 18% to $4.8B and stockholders equity grew 22% to $2.2B, while debt decreased 17% to $1.0B, indicating a strengthening balance sheet. However, operational performance deteriorated with net income falling 14% to $227M and operating cash flow declining 27% to $261M, suggesting the company is investing heavily in growth but facing near-term profitability headwinds. The 22-25% increases in accounts receivable and inventory, combined with lower cash generation, indicate working capital challenges typical of rapid expansion phases.

FINANCIAL STATEMENT CHANGES
Dividends Paid
Cash Flow
+29%
$17.0M$21.9M

Dividend payments increased 29% — management confidence in sustained cash generation.

Operating Cash Flow
Cash Flow
-26.7%
$355.4M$260.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Cash & Equivalents
Balance Sheet
-25.5%
$249.4M$185.9M

Cash decreased 25.5% — monitor burn rate and upcoming capital needs.

Stockholders Equity
Balance Sheet
+22.4%
$1.8B$2.2B

Equity base grew 22.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+21.9%
$370.3M$451.3M

Receivables grew 21.9% — monitor days sales outstanding for collection efficiency.

Inventory
Balance Sheet
+19.3%
$403.7M$481.8M

Inventory built 19.3% — monitor whether demand supports this build or if write-downs may follow.

Total Assets
Balance Sheet
+18.1%
$4.0B$4.8B

Asset base grew 18.1% — expansion through organic growth, acquisitions, or capital deployment.

Total Debt
Balance Sheet
-16.5%
$1.2B$1.0B

Debt reduced 16.5% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
+14.8%
$2.2B$2.6B

Liabilities increased 14.8% — monitor debt-to-equity ratio and interest coverage.

Net Income
P&L
-14.4%
$264.8M$226.8M

Net income declined 14.4% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-20
ADDED
During the year ended December 31, 2025, we completed four acquisitions and we expect to complete more acquisitions in the future.
We are subject to specific risks associated with international operations of this Form 10-K.
Research and development expens e was $44.0 million, $39.2 million and $38.8 million for the years ended December 31, 2025, 2024 and 2023, respectively .
Risk Factors Risks Related to Our Business of this Form 10-K.
Medical Device Regulation So me of our gas control products are related to medical device products and are subject to extensive regulation by the United States Food and Drug Administration, European Union Medical Device Regulation and numerous other federal, state and foreign governmental authorities.
+7 more — sign up free →
REMOVED
During the year ended December 31, 2024, we completed three acquisitions and we expect to complete more acquisitions in the future.
See Part II, Item 8, Note 5, Acquisitions of this Form 10-K for further information.
Research and development expens e was $39.2 million, $38.8 million and $36.0 million for the years ended December 31, 2024, 2023 and 2022, respectively .
So me of our gas control products are related to medical device products and are subject to extensive regulation by the United States Food and Drug Administration (the FDA ), European Union Medical Device Regulation (the EU MDR ) and numerous other federal, state and foreign governmental authorities.
Human Capital Management Employee Profile As of December 31, 2024, we employed approximately 9,300 associates, of whom approximately 1,300 were employed in the United States and approximately 8,000 were employed outside of the United States.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →